Esperion Therapeutics

Esperion Therapeutics, Inc. is a public American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

Esperion Therapeutics, Inc.

Type	Public
Traded as	NASDAQ: ESPR Russell 2000 Component
Industry	Pharmaceutical
Founded	2008
Founder	Dr. Roger Newton
Headquarters	Ann Arbor, Michigan
Key people	Timothy M. Mayleben (president and CEO)
Net income	(US$26.1 million) (2013) (US$11.7 million) (2012)
Total assets	US$78.3 million (2013) US$7.31 million (2012)
Website	Esperion.com
Footnotes / references financial information[1]^:F-3,4

History

Pfizer acquired the original Esperion in 2004 for US$1,300,000,000 as a defensive move to prevent ETC-216 from falling into competitors' hands.[2]^:165 Two years later, in 2006, Pfizer decided to kill the Esperion organization and development of ETC-216. In May 2008, Dr. Roger Newton, Esperion's founder and chief scientific officer, raised sufficient capital to acquire rights to ETC-1002 and Esperion from Pfizer, thereby leading to a second independent period for the company.[2]^:165[3][4] In June 2013, Esperion became a public company again through an initial public offering.[5] As of April 2014, Esperion was traded on NASDAQ under the symbol "ESPR".[6]

Products

The company's main products are NEXLIZET (bempedoic acid and ezetimibe) and NEXLETOL (bempedoic acid), the first approved oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering combination medicine that is now available in U.S. pharmacies.

References

1. "Esperion Therapeutics, Inc". EDGAR. Form 10-K. U.S. Securities and Exchange Commission. March 13, 2014. Commission File Number:001-35986.
2. Li, Jie Jack (2009). Triumph of the Heart: The Story of Statins. Oxford University Press. ISBN 9780195323573.
3. "History". Esperion Therapeutics. Archived from the original on April 29, 2012.
4. Catherine Shaffer (2008). "Pfizer jettisons Esperion". Nat. Biotechnol. 26 (7): 724–725. doi:10.1038/nbt0708-724.
5. Huggett, Brady (December 2013). "Burning Bright". Nat. Biotechnol. 31 (12). pp. 1068–71.
6. "ESPR stock quote". NASDAQ. Retrieved April 22, 2014.

Further reading

• Afuah, Allan (2009). "Case 10 - Esperion: Drano for your Arteries". Strategic Innovation: New Game Strategies for Competitive Advantage. Routledge. ISBN 9781135840501.